Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort.


Journal

The international journal of neuropsychopharmacology
ISSN: 1469-5111
Titre abrégé: Int J Neuropsychopharmacol
Pays: England
ID NLM: 9815893

Informations de publication

Date de publication:
20 01 2021
Historique:
received: 03 04 2020
revised: 02 08 2020
accepted: 21 08 2020
pubmed: 26 8 2020
medline: 29 1 2022
entrez: 26 8 2020
Statut: ppublish

Résumé

Patients with a first episode of psychosis (FEP) are at higher risk of gaining weight and presenting metabolic disturbances, partly related to antipsychotic exposure. Previous studies suggest that treatment discontinuation might have a positive impact on weight in schizophrenia. The aim of this study was to evaluate the effect of treatment discontinuation on weight and metabolic changes in a FEP cohort. A total of 209 FEP patients and 57 healthy controls were evaluated at study entry and prospectively at 10-year follow-up. Anthropometric measures and, clinical, metabolic, and sociodemographic data were collected. Patients discontinuing antipsychotic treatment presented a significantly lower increase in weight and better metabolic parameter results than those still on antipsychotic treatment at 10-year follow-up. Treatment discontinuation had a positive effect on the weight and metabolic changes observed in FEP patients; however, this effect was not sufficient to reaching a complete reversal to normal levels.

Sections du résumé

BACKGROUND
Patients with a first episode of psychosis (FEP) are at higher risk of gaining weight and presenting metabolic disturbances, partly related to antipsychotic exposure. Previous studies suggest that treatment discontinuation might have a positive impact on weight in schizophrenia. The aim of this study was to evaluate the effect of treatment discontinuation on weight and metabolic changes in a FEP cohort.
METHODS
A total of 209 FEP patients and 57 healthy controls were evaluated at study entry and prospectively at 10-year follow-up. Anthropometric measures and, clinical, metabolic, and sociodemographic data were collected.
RESULTS
Patients discontinuing antipsychotic treatment presented a significantly lower increase in weight and better metabolic parameter results than those still on antipsychotic treatment at 10-year follow-up.
CONCLUSIONS
Treatment discontinuation had a positive effect on the weight and metabolic changes observed in FEP patients; however, this effect was not sufficient to reaching a complete reversal to normal levels.

Identifiants

pubmed: 32840607
pii: 5897000
doi: 10.1093/ijnp/pyaa066
pmc: PMC7816683
doi:

Substances chimiques

Antipsychotic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-7

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of CINP.

Références

Schizophr Res. 2018 Mar;193:188-196
pubmed: 28663026
JAMA Psychiatry. 2017 Mar 1;74(3):261-269
pubmed: 28097367
World Psychiatry. 2017 Oct;16(3):308-315
pubmed: 28941119
Acta Psychiatr Scand. 2016 Jan;133(1):63-75
pubmed: 26252780
J Child Adolesc Psychopharmacol. 2017 Dec;27(10):897-907
pubmed: 28880609
Lancet Psychiatry. 2018 May;5(5):432-442
pubmed: 29551618
Early Interv Psychiatry. 2010 Feb;4(1):57-63
pubmed: 20199481
J Clin Psychiatry. 2017 Sep/Oct;78(8):e1035-e1046
pubmed: 28102978
J Clin Psychiatry. 2016 Apr;77(4):492-500
pubmed: 26759992
Psychopharmacology (Berl). 2018 Jan;235(1):245-255
pubmed: 29075885
Schizophr Res. 2016 Jul;174(1-3):120-125
pubmed: 27157800
World Psychiatry. 2018 Oct;17(3):365-367
pubmed: 30192082
Eur Psychiatry. 2012 Jan;27(1):50-5
pubmed: 21036552
J Clin Psychiatry. 2007 Nov;68(11):1733-40
pubmed: 18052567
Psychol Med. 2019 Nov 18;:1-14
pubmed: 31736458
PLoS One. 2016 Feb 16;11(2):e0149209
pubmed: 26882230
Neuropsychiatr Dis Treat. 2014 Jul 22;10:1361-8
pubmed: 25092981
Early Interv Psychiatry. 2016 Jun;10(3):193-202
pubmed: 25962699
J Clin Psychiatry. 2009 Jul;70(7):990-6
pubmed: 19497244
World Psychiatry. 2017 Jun;16(2):217-218
pubmed: 28498600
Acta Psychiatr Scand. 2009 Mar;119(3):171-9
pubmed: 19178394
Schizophr Res. 2014 Oct;159(1):90-4
pubmed: 25151200
Int J Neuropsychopharmacol. 2014 Jan;17(1):41-51
pubmed: 24103107

Auteurs

Javier Vázquez-Bourgon (J)

Department of Psychiatry, University Hospital Marqués de Valdecilla - Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.

Jaqueline Mayoral-van Son (J)

Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBiS, Sevilla, Spain.

Marcos Gómez-Revuelta (M)

Department of Psychiatry, University Hospital Marqués de Valdecilla - Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.

María Juncal-Ruiz (M)

Department of Psychiatry, Hospital Sierrallana - Instituto de Investigacion Marques de Valdecilla (IDIVAL), Torrelavega, Spain.
Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.

Víctor Ortiz-García de la Foz (V)

Department of Psychiatry, University Hospital Marqués de Valdecilla - Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.

Diana Tordesillas-Gutiérrez (D)

Department of Psychiatry, University Hospital Marqués de Valdecilla - Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.

Rosa Ayesa-Arriola (R)

Department of Psychiatry, University Hospital Marqués de Valdecilla - Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain.

Miquel Bioque (M)

Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Benedicto Crespo-Facorro (B)

Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBiS, Sevilla, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH